NewcureM

NewcureM is a South Korean biotechnology company dedicated to developing next-generation cancer immunotherapies by targeting the tumor microenvironment (TME). The company utilizes a proprietary platform to identify metabolic and immunological barriers that prevent the immune system from effectively attacking cancer cells. Its lead candidate, NM-101, is a potent small molecule inhibitor of CD73, an enzyme that generates immunosuppressive adenosine within the TME. By blocking this pathway, NewcureM aims to restore the activity of T cells and natural killer cells, potentially improving outcomes for patients with various solid tumors. The company's pipeline also includes adenosine receptor antagonists and other novel TME-remodeling agents designed for use as both monotherapies and in combination with existing immune checkpoint inhibitors.